Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety and Efficacy of VAY736 in Patients With Primary Sjogren's Syndrome (pSS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02962895
Recruitment Status : Recruiting
First Posted : November 15, 2016
Last Update Posted : January 9, 2019
Sponsor:
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )

Brief Summary:
This study will determine the dose-response relationship of VAY736 for key efficacy and safety parameters

Condition or disease Intervention/treatment Phase
Primary Sjogren's Syndrome Biological: VAY736 Other: Placebo Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 180 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: Study of Safety and Efficacy of Multiple VAY736 Doses in Patients With Moderate to Severe Primary Sjogren's Syndrome (pSS)
Actual Study Start Date : June 27, 2017
Estimated Primary Completion Date : June 30, 2020
Estimated Study Completion Date : June 30, 2020

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: VAY736 dose 1
VAY736 low
Biological: VAY736
VAY736

Experimental: VAY736 dose 2
VAY736 medium
Biological: VAY736
VAY736

Experimental: VAY736 dose 3
VAY736 high
Biological: VAY736
VAY736

Placebo Comparator: Placebo
Placebo control
Other: Placebo
Placebo control




Primary Outcome Measures :
  1. Dose response [ Time Frame: 24 weeks ]
    Dose response measured by change multi-dimensional disease activity as assessed by the physician


Secondary Outcome Measures :
  1. Dose response [ Time Frame: 24 weeks ]
    Dose response measured by change in patient-reported disease activity measures

  2. Quality of Life [ Time Frame: 24 weeks ]
    Change in quality of life measure by PRO

  3. Salivary gland function [ Time Frame: 24 weeks ]
    Change in salivary gland function measure by flow rate

  4. Safety [ Time Frame: 24 weeks ]
    Incidence of Adverse events and Serious Adverse Events



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Fulfilled revised American European Consensus Group criteria for pSS
  • Seropositive at screening for anti-Ro/SSA antibodies
  • Screening ESSDAI value >=6 scored from 7 domains: articular, cutaneous, glandular, lymphoadenopathy, constitutional, biologic and hematologic.

Exclusion Criteria:

  • Secondary Sjogren's syndrome
  • Use of other investigational drugs
  • Active viral, bacterial or other infections
  • Positive hepatitis B, hepatitis C, HIV or tuberculosis test results at screening

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02962895


Contacts
Layout table for location contacts
Contact: Novartis Pharmaceuticals 1-888-669-6682 novartis.email@novartis.com
Contact: Novartis Pharmaceuticals +41613241111

  Show 72 Study Locations
Sponsors and Collaborators
Novartis Pharmaceuticals

Layout table for additonal information
Responsible Party: Novartis Pharmaceuticals
ClinicalTrials.gov Identifier: NCT02962895     History of Changes
Other Study ID Numbers: CVAY736A2201
First Posted: November 15, 2016    Key Record Dates
Last Update Posted: January 9, 2019
Last Verified: January 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided
Plan Description:

Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.

This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com


Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Novartis ( Novartis Pharmaceuticals ):
Sjogren, VAY736, ianalumab

Additional relevant MeSH terms:
Layout table for MeSH terms
Xerostomia
Mouth Diseases
Dry Eye Syndromes
Syndrome
Sjogren's Syndrome
Disease
Pathologic Processes
Arthritis, Rheumatoid
Arthritis
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Salivary Gland Diseases
Stomatognathic Diseases
Lacrimal Apparatus Diseases
Eye Diseases
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases